InsidersTradesSigma
Follow the 엔지켐생명과학 share price and the full directors' dealings record of the company, a listed issuer based in South Korea. Shares are quoted on the KR market, under the supervision of DART (FSS). Operating in the Health Care sector, 엔지켐생명과학 has published 113 public disclosures. Market capitalisation: €83.8bn. The latest transaction was filed on 1 June 2026 (Purchase). Among the most active insiders: 윤영배. The full history is openly available.
108
Insider Decl.
n/a
Thresholds
€3m
61 ops.
Buy Volume
n/a
n/a
Sell Volume
22Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 28,598 of 29,063 companies
8.7
score / 100
Value12
Quality6
FCF yld-14%
Earn yld-22%
EV/EBITDA·
ROE·
Gross mgn5.0%
Net mgn-27%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 1 June 2026
Declarations113 total
Other
Other
Other
Other
Other
1,105,852 sharesKRXDART:20260508001022
0KRXDART:20260420000485
0KRXDART:20260318000393
0KRXDART:20260311004127
6,625,447 sharesKRXDART:20260227008612
23,240 sharesKRXDART:20251202000228
0KRXDART:20241227000537
0KRXDART:20241108000392
0KRXDART:20240926000317
0KRXDART:20240812000689
0KRXDART:20240715000103
0KRXDART:20240702000407
25 of 113 declarations
关于 엔지켐생명과학
엔지켐생명과학是一家在XKRX市场上市的医疗保健和制药领域的公司。它专注于开发创新的疾病治疗解决方案。